CG ONCOLOGY, INC.

Communiqués CG Oncology, Inc.

Actions

CGON

US1569441009

Temps réel estimé Cboe BZX Autres places de cotation 19:37:55 17/07/2024			Varia. 5j.	Varia. 1 janv.
37,54 ^USD	-0,31 %		+13,88 %	0,00 %

28/06	Mise à jour sectorielle : Les actions du secteur de la santé déclinent en fin d'après-midi	MT
28/06	Mise à jour sectorielle : Les actions du secteur de la santé en hausse dans l'après-midi	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Bladder Cancer Pipeline 2024 \| UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology Inc., Ferring Pharma	09/07	AQ
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec	18/06	AQ
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC	06/06	AQ
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting	24/05	AQ
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates	09/05	AQ
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	06/05	AQ
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	03/05	AQ
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024	26/04	AQ
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024	24/04	AQ
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting	28/03	AQ
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer	27/02	AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares	31/01	AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	30/01	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Nos Contenus Gratuits vous Aident à Sécuriser et Augmenter la Performance de vos Investissements

Sécuriser mes Investissements

fermer